Published in J Clin Invest on July 01, 2008
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer (2009) 4.15
The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood (2009) 3.56
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia (2012) 3.04
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood (2010) 2.59
Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol (2009) 2.48
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood (2009) 2.39
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood (2012) 2.37
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood (2011) 2.34
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol (2013) 2.33
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood (2010) 2.33
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood (2011) 2.09
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia (2013) 2.04
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med (2015) 1.92
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol (2010) 1.77
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res (2009) 1.74
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol (2014) 1.65
Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol (2009) 1.64
Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol (2013) 1.63
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A (2009) 1.61
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood (2013) 1.61
Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia. Biol Blood Marrow Transplant (2011) 1.47
N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. Leuk Lymphoma (2009) 1.42
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood (2015) 1.39
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol (2012) 1.38
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica (2009) 1.31
Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood (2010) 1.31
Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model. Blood (2015) 1.27
Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am (2013) 1.22
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica (2013) 1.21
Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol (2010) 1.20
Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol (2010) 1.07
Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One (2013) 1.02
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res (2014) 1.01
Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol (2012) 1.01
Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv Hematol (2012) 1.00
Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia (2015) 0.99
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta (2015) 0.98
Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica (2009) 0.96
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood (2013) 0.96
Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia (2010) 0.93
Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer (2009) 0.93
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol (2014) 0.93
The immunological synapse. Cancer Immunol Res (2014) 0.93
Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. J Immunother (2010) 0.93
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia (2013) 0.92
Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma (2010) 0.92
Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. Haematologica (2014) 0.92
Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Front Biosci (Schol Ed) (2012) 0.91
Initial treatment of CLL: integrating biology and functional status. Blood (2015) 0.90
Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood (2014) 0.90
How will B-cell-receptor-targeted therapies change future CLL therapy? Blood (2014) 0.90
Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leuk Lymphoma (2011) 0.90
T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases. J Immunol (2013) 0.89
Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer (2015) 0.88
Adoptive T-cell therapy for B-cell malignancies. Expert Rev Hematol (2009) 0.88
Immunological aspects in chronic lymphocytic leukemia (CLL) development. Ann Hematol (2012) 0.88
Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int (2014) 0.86
Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res (2012) 0.86
Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease. PLoS One (2014) 0.86
Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy. Haematologica (2012) 0.85
Targeting inflammatory pathways in chronic lymphocytic leukemia. Crit Rev Oncol Hematol (2013) 0.85
B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia. Haematologica (2015) 0.85
Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia (2011) 0.85
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica (2013) 0.85
HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. Haematologica (2013) 0.85
Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Semin Oncol (2016) 0.84
Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. Cancer Immunol Immunother (2010) 0.84
The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. Leukemia (2015) 0.84
Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia. Blood (2011) 0.84
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia (2014) 0.84
The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease. Oncotarget (2015) 0.83
The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. Ann Hematol (2013) 0.83
Lymphoma: immune evasion strategies. Cancers (Basel) (2015) 0.82
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Haematologica (2014) 0.82
Numbers and cytotoxicities of CD3+CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia. Cancer Biol Ther (2013) 0.82
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma. BMC Cancer (2012) 0.82
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood (2015) 0.82
Lenalidomide and chronic lymphocytic leukemia. Biomed Res Int (2013) 0.81
Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk Res (2010) 0.81
Immunotherapy of acute myeloid leukemia based on γδ T cells. Oncoimmunology (2012) 0.81
How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program (2010) 0.81
Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses. Cancer Gene Ther (2015) 0.80
B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia. Leukemia (2016) 0.79
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). Ther Adv Hematol (2016) 0.79
Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model. Br J Haematol (2015) 0.79
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. Biol Blood Marrow Transplant (2016) 0.78
Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. World J Stem Cells (2015) 0.78
Lenalidomide in the treatment of chronic lymphocytic leukemia. Adv Hematol (2012) 0.78
CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia. Haematologica (2010) 0.78
Immune reconstitution in chronic lymphocytic leukemia. Curr Hematol Malig Rep (2012) 0.78
Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date. World J Clin Cases (2015) 0.78
TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia. Cell Death Dis (2016) 0.78
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clin Cancer Res (2016) 0.78
The immunological synapse: a molecular machine controlling T cell activation. Science (1999) 17.41
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med (2005) 8.80
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med (2001) 5.66
Immune surveillance of tumors. J Clin Invest (2007) 5.04
Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A (2002) 4.86
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2008) 4.61
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol (2006) 3.95
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol (2003) 3.38
Regulation of T-cell activation by the cytoskeleton. Nat Rev Immunol (2007) 3.19
Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med (1993) 3.04
Regulated expression of Mg2+ binding epitope on leukocyte integrin alpha subunits. EMBO J (1989) 2.84
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood (2005) 2.81
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol (2008) 2.79
Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med (1998) 2.39
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest (2005) 2.15
Wasp recruitment to the T cell:APC contact site occurs independently of Cdc42 activation. Immunity (2001) 1.93
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood (2006) 1.92
Dynamin 2 regulates T cell activation by controlling actin polymerization at the immunological synapse. Nat Immunol (2005) 1.90
Human immunodeficiency virus type-1 infection impairs the formation of the immunological synapse. Immunity (2006) 1.90
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood (2005) 1.89
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood (2006) 1.88
Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol (2008) 1.87
Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci U S A (1995) 1.75
Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells. Cancer Res (2007) 1.58
Harnessing the immune system to treat cancer. J Clin Invest (2007) 1.57
Modulation of the immunological synapse: a key to HIV-1 pathogenesis? Nat Rev Immunol (2007) 1.57
CD28 interaction with filamin-A controls lipid raft accumulation at the T-cell immunological synapse. Nat Cell Biol (2006) 1.56
T cell anergy and costimulation. Immunol Rev (2003) 1.52
TCR, LFA-1, and CD28 play unique and complementary roles in signaling T cell cytoskeletal reorganization. J Immunol (1999) 1.50
Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma (2003) 1.50
The immunological synapse: integrins take the stage. Immunol Rev (2002) 1.47
Itk functions to control actin polymerization at the immune synapse through localized activation of Cdc42 and WASP. Curr Biol (2003) 1.47
The role of the integrin LFA-1 in T-lymphocyte migration. Immunol Rev (2007) 1.47
Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function. J Immunol (2005) 1.44
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood (2001) 1.43
Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med (2000) 1.38
Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood (2002) 1.31
Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med (1994) 1.28
Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med (1997) 1.26
T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood (2002) 1.12
Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood (2001) 0.90
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 16.33
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (2011) 5.98
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med (2014) 4.98
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood (2010) 4.69
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A (2010) 3.86
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
Adult Burkitt leukemia and lymphoma. Blood (2004) 3.46
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood (2008) 3.19
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol (2005) 3.05
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2011) 3.01
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood (2014) 2.94
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 2.91
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol (2008) 2.79
Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches. Oncology (Williston Park) (2012) 2.73
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood (2010) 2.72
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 2.66
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood (2012) 2.65
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol (2007) 2.64
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood (2009) 2.39
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood (2004) 2.39
The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood (2012) 2.39
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood (2012) 2.37
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell (2010) 2.37
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol (2012) 2.36
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol (2009) 2.34
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood (2012) 2.27
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol (2011) 2.26
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst (2002) 2.22
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest (2005) 2.15
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clin Cancer Res (2005) 2.10
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J (2007) 2.08
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood (2010) 2.07
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma (2009) 2.06
Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Br J Haematol (2013) 2.06
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood (2013) 2.03
Atypical lymphocytic lobular panniculitis. J Cutan Pathol (2004) 2.02
Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood (2004) 2.01
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol (2002) 1.98
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood (2012) 1.97
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood (2006) 1.92
FLT3 mutations in childhood acute lymphoblastic leukemia. Blood (2003) 1.91
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood (2008) 1.90
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood (2009) 1.83
Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis (2006) 1.78
Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 1.73
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol (2004) 1.70
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res (2005) 1.69
Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol (2006) 1.68
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res (2009) 1.65
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol (2014) 1.65
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol (2011) 1.65